Acyclic retinoid inhibits functional interaction of transcription factors Krüppel-like factor 5 and retinoic acid receptor-alpha

FEBS Letters

Volumn 582, Issue 12, 2008, Pages 1755-1760

  Kada, Nanae ^a   Suzuki, Toru ^a   Aizawa, Kenichi ^a   Munemasa, Yoshiko ^a   Matsumura, Takayoshi ^a   Sawaki, Daigo ^a   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Transcription; Vascular biology

Indexed keywords

KRUPPEL LIKE FACTOR; KRUPPEL LIKE FACTOR 5; PLATELET DERIVED GROWTH FACTOR A; POLYPRENOIC ACID; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; SOYBEAN OIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BINDING ASSAY; CARDIOVASCULAR SYSTEM; CELL GROWTH; CONTROLLED STUDY; DRUG MECHANISM; GROWTH INHIBITION; IMMUNOPRECIPITATION; INHIBITION KINETICS; LIMB ISCHEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; TISSUE REPAIR; TRANSACTIVATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CATTLE; CELLS, CULTURED; IMMUNOPRECIPITATION; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, RETINOIC ACID; TRANSCRIPTION, GENETIC; TRETINOIN;

EID: 43549087075     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2008.04.040     Document Type: Article

References (18)

1. Shindo T., Manabe I., Fukushima Y., Tobe K., Aizawa K., Miyamoto S., Kowase K., Moriyama N., Imai Y., Kawakami H., Nishimatsu H., Ishikawa T., Suzuki T., Morita H., Maemura K., Sata M., Hirata Y., Komukai M., Kagechika H., Kadowaki T., Kurabayashi M., and Nagai R. Krüppel-like zinc-finger transcription factor 5 KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat. Med. 8 (2002) 856-863
2. Fujiu K., Manabe I., Ishihara A., Oishi Y., Iwata H., Nishimura G., Shindo T., Maemura K., Kagechika H., Shudo K., and Nagai R. Synthetic retinoid Am80 suppresses smooth muscle phenotypic modulation and in-stent neointima formation by inhibiting KLF5. Circ. Res. 97 (2005) 1132-1141
3. Muto Y., Moriwaki H., Ninomiya M., Adachi S., Saito A., Takasaki K., Tanaka T., Tsurumi K., Okuno M., Tomita E., Nakamura T., and Kojima T. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. New Engl. J. Med. 334 (1996) 1561-1567
4. Ralhan R., and Kaur J. Retinoids as chemopreventive agents. J. Biol. Regul. Homeost. Agents 17 (2003) 66-91
5. Kada N., Suzuki T., Aizawa K., Matsumura T., Ishibashi N., Suzuki N., Takeda N., Munemasa Y., Sawaki D., Ishikawa T., and Nagai R. Acyclic retinoid inhibits neointima formation through retinoic acid receptor beta-induced apoptosis. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 1535-1541
6. Miyamoto S., Suzuki T., Muto S., Aizawa K., Kimura A., Mizuno Y., Nagino T., Imai Y., Adachi N., Horikoshi M., and Nagai R. Positive and negative regulation of the cardiovascular transcription factor KLF5 by p300 and the oncogenic regulator SET through interaction and acetylation on the DNA-binding domain. Mol. Cell Biol. 23 (2003) 8528-8541
7. Aizawa K., Suzuki T., Kada N., Ishihara A., Kowase K., Matsumura T., Sasaki K., Munemasa Y., Manabe I., Kurabayashi M., Collins T., and Nagai R. Regulation of platelet-derived growth factor-A chain by Krüppel-like factor 5: new pathway of cooperative activation with nuclear factor-kappaB. J. Biol. Chem. 279 (2004) 70-76
8. Suzuki T., Kimura A., Nagai R., and Horikoshi M. Regulation of interaction of the acetyltransferase region of p300 and the DNA-binding domain of Sp1 on and through DNA binding. Genes Cell 5 (2000) 29-41
9. Couffinhal T., Silver M., Zheng L.P., Kearney M., Witzenbichler B., and Isner J.M. Mouse model of angiogenesis. Am. J. Pathol. 152 (1998) 1667-1679
10. Kojima S., Okuno M., Matsushima-Nishiwaki R., Friedman S.L., and Moriwaki H. Acyclic retinoid in the chemoprevention of hepatocellular carcinoma. Int. J. Oncol. 24 (2004) 797-805
11. Mackay J.P., and Crossley M. Zinc fingers are sticking together. Trends Biochem. Sci. 23 (1998) 1-4
12. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., and Evans R.M. The nuclear receptor super family: the second decade. Cell 83 (1995) 835-839
13. Sánchez Alvarado A., and Newmark P.A. Double-stranded RNA specifically disrupts gene expression during planarian regeneration. Proc. Natl. Acad. Sci. USA 96 (1999) 5049-5054
14. Pai S.I., Lin Y.Y., Macaes B., Meneshian A., Hung C.F., and Wu T.C. Prospects of RNA interference therapy for cancer. Gene Ther. 13 (2006) 464-477
15. Campochiaro P.A. Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. Gene Ther. 13 (2006) 559-562
16. Lonard D.M., and O'malley B.W. Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol Cell. 27 (2007) 691-700
17. Suzuki Y., Shimada J., Shudo K., Matsumura M., Crippa M.P., and Kojima S. Physical interaction between retinoic acid receptor and Sp1: mechanism for induction of urokinase by retinoic acid. Blood 93 (1999) 4264-4274
18. Zhang X.L., Zhang D., Michel F.J., Blum J.L., Simmen F.A., and Simmen R.C. Selective interactions of Kruppel-like factor 9/basic transcription element-binding protein with progesterone receptor isoforms A and B determine transcriptional activity of progesterone-responsive genes in endometrial epithelial cells. J. Biol. Chem. 278 (2003) 21474-21482